


Construction of drug development platform of disease-specific degradation by CANDDY (FuturedMe Inc.)



City	Year of Establishment	Founder
Chuo-ku, Tokyo	2018	Etsuko Miyamoto-Sato

Partner VC	Latest round of Fundraising	Valuation
UntroD Capital Japan, Inc.	Series A	JPY 700 million

Contact Information :
tel : +81-4-7197-6230

Website : <https://futuresme.com/jp/#secMV>

○ Business Plan

In the era of precision medicine, genomic medicine needs to solve the problem (pain) that even if the causative molecule (target) of a disease is identified, there is no therapeutic drug for the target. To this end, we will raise the barrier to entry for CANDDY, the next-generation degradative drug discovery technology, and build a disease-specific degradative drug development platform that will establish a differentiated prototype, expand the market, and reduce side effects.

○ Research Outline

We are developing a disease-selective CANDDY platform that enables targeted protein degradation specifically in cancer cells by exploiting proteasome isoform differences.

① Disease-Selective CATs:

Demonstrating safety and potential applicability across hematologic cancers, solid tumors, and autoimmune diseases.

② CANCER_Showcase Data:

Generating in vitro degradation results and in vivo safety and efficacy data.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2025-2027FY	JPY 200 million	-